Introduction
Cancer, IVH, PNH, organ damage, hemolysis, Fatigue
HEMATOLOGICAL DISORDER, THROMBOEMBOLIC EVENT, CHRONIC ILLNESS, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), HEMOLYSIS, PNH, CANCER
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, hematological disorder characterized by uncontrolled terminal complement pathway activation leading to intravascular hemolysis (IVH), as indicated by elevated lactate dehydrogenase (LDH) levels, thromboembolic events, and organ damage [Eculizumab is a first-generation C5 inhibitor and the first disease-specific treatment to be approved for patients with PNH, offering terminal complement inhibition through a biweekly intravenous dosing regimen [Improvements observed in PROs following C5 inhibitor treatment for PNH in studies 301 and 302 have been reported using the Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F) and the European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire–Core 30 (EORTC QLQ-C30) [Data collected from a cohort of complement inhibitor-naive patients with PNH in study 301 were used for this 